



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Xiao et al.

Group Art Unit: Not yet assigned

Serial No.: 10/602,350

Conf. No.: 7786

Filed: Herewith

 For: Methods and Compositions  
 for The Treatment of Cancer

Examiner: Not yet assigned

 I hereby certify that this correspondence is being deposited with the  
 United States Postal Service with sufficient postage as First Class  
 Mail in an envelope addressed to: Mail Stop Supplemental IDS-Non-  
 Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
 22313-1450 on:

Date of Deposit:

Person making Deposit:

Signature:

Date of Signature:

5/24/2004

5/24/2004

BONNIE FERGUSON

Bonnie Ferguson

5/24/2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

 Commissioner for Patents  
 Alexandria, VA 22313-1450

Dear Sir:

The references listed on the attached PTO-1449 form are being brought to the attention of the Examiner under 37 C.F.R. §1.97(c) for consideration in connection with the examination of the above-identified patent application. None of these publications are admitted to be prior art to the presently claimed invention, but are deemed of sufficient relevance to be brought to the attention of the Examiner.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

17512(HL)  
Serial No. 10/602,350


PATENT

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 form with initials or other appropriate marks.

No fee is believed due in connection with this communication in accordance with 37 C.F.R. § 1.97(c) and 37 C.F.R. § 1.97(e). However, if Applicant is in error, please charge any fees that may be due in connection with this Information Disclosure Statement to Deposit Account No. 01-0885.

Respectfully submitted,

Date: 5/21/04



Carlos A. Fisher  
Reg. No. 36,510  
ALLERGAN, INC.  
T2-7H  
2525 Dupont Drive  
Irvine, CA 92612  
Tel: 714-246-4920  
Fax: 714-246-4249



**LIST OF REFERENCES CITED BY APPLICANT**

<b>ATTY. DOCKET:</b> 17512(HL)	<b>SERIAL NO.:</b> 10/602,350
<b>APPLICANT:</b> Xiao et al	<b>TITLE: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER</b>
<b>FILING DATE:</b> June 23, 2003	<b>GROUP:</b> 1614

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

**OTHER REFERENCES**

(Including Author, Title, Date, Pertinent Pages, etc.)

BA	Feng et al. Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. Genes Dev. 1997, Vol. 11, pages 59-71
BB	Stewart et al, Retinoids differentially regulate the proliferation of colon cancer cells lines. Exp. Cell Res. 1997, Vol. 233, pages 321-329.
BC	Sheikh et al, Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem. 26 August 1994, Vol. 269, No. 34, pages 21440-21447.
BD	Sato et al, Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of (PPAR) gamma agonists, Br. J. Cancer. 2000, Vol. 83, No. 10, pages 1394-140

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.